Impact of NSAID etoricoxib on side effects of orthodontic tooth movement

Ann Anat. 2020 Nov:232:151585. doi: 10.1016/j.aanat.2020.151585. Epub 2020 Aug 18.

Abstract

Objectives: The non-steroidal anti-inflammatory drug etoricoxib is the most highly selective inhibitor of cyclooxygenase-2 available (344:1) and has been approved for postoperative pain therapy following dental interventions in Europe. At clinically relevant doses it has been reported to only have marginal effects on the velocity of orthodontic tooth movement (OTM). Its effects on associated dental root resorptions, osteoclastogenesis, trabecular number in the alveolar bone and periodontal bone loss during OTM, however, have not yet been investigated.

Material and methods: 40 male Fischer344 rats were divided into four groups: 1.5ml tap water/day p.o. (control, 1), additional 7.8mg/kg/day etoricoxib (normal dose) for three (2) or seven (3) days/week and 13.1mg/kg/day (high dose) for seven days/week, respectively (4). After a week of premedication, OTM in anterior direction of the first left upper molar was performed for 28 days by means of a nickel-titanium coil spring (0.25N). We quantified OTM-associated dental root resorptions, osteoclastogenesis, trabecular number and periodontal bone loss by histomorphometrical, histochemical and μCT analyses of the disected tooth-bearing upper jaw sections.

Results: After 28 days of OTM, associated reduction of trabecular number seemed to be slightly alleviated by high doses of etoricoxib, whereas no significant other etoricoxib effects in the doses administered could be detected regarding OTM-induced or -associated dental root resorptions, osteoclastogenesis or periodontal bone loss.

Conclusions: Dental root resorptions, osteoclastogenesis and periodontal bone loss during OTM in rats were not significantly affected by etoricoxib in the clinically relevant dosages investigated with only a slight inhibitory effect on bone remodelling to be expected at high dosages. Etoricoxib is therefore not suitable for the prevention of these detrimental effects, but could be a suitable analgesic during OTM, as it has been reported not to affect tooth movement.

Keywords: Etoricoxib; NSAID; Orthodontic tooth movement; Osteoclastogenesis; Root resorptions; μCT.

MeSH terms

  • Alveolar Bone Loss / drug therapy
  • Alveolar Bone Loss / prevention & control
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Bone Remodeling / drug effects
  • Etoricoxib / pharmacology*
  • Etoricoxib / therapeutic use
  • Male
  • Models, Animal
  • Osteogenesis / drug effects
  • Pain / drug therapy
  • Pain / etiology
  • Rats, Inbred F344
  • Staining and Labeling
  • Tartrate-Resistant Acid Phosphatase
  • Tooth Movement Techniques / adverse effects*
  • Tooth Resorption / drug therapy
  • Tooth Resorption / prevention & control

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Tartrate-Resistant Acid Phosphatase
  • Etoricoxib